Search - tctmd.com

Displaying 1 - 19 of 19

Sort: Relevancy | Date

News Daily News

Top Endovascular News of 2023

L.A. McKeown

December 28, 2023

News Conference News AHA 2023

Inflammation More Powerful Than LDL as CV Risk Predictor in Statin-Free Patients

Caitlin E. Cox

November 07, 2023

News Daily News

Two New Studies Highlight Lack of Diversity in Cardiovascular RCTs

Michael O'Riordan

July 11, 2023

News Conference News AHA 2022

Common ‘Heart’ Supplements Can’t Beat Statins: SPORT

Michael O'Riordan

November 06, 2022

News Daily News

USPSTF: Most Vitamin, Supplement Data Still ‘Inconclusive’ on CVD Benefits

Yael L. Maxwell

June 23, 2022

News Daily News

Skipping Low-Value Cardiovascular Care Could Save Billions: AHA

Michael O'Riordan

March 01, 2022

News Daily News

Homozygous FH Diagnosis Often Comes Late, With Lackluster Care

Michael O'Riordan

February 10, 2022

News Daily News

FDA Issues New Guidance on Sodium Targets for Food Industry

L.A. McKeown

October 14, 2021

News Daily News

Could an App Replace Statin Prescribing by Doctors?

Michael O'Riordan

September 08, 2021

News Daily News

New VARC-3 Definitions Provide a Road Map for Future Aortic Valve Research

Michael O'Riordan

April 23, 2021

News Features

Funding the Future: How Industry Support for CV Trials Could Evolve

Michael O'Riordan

December 17, 2020

COLCOT Renews Hope for Anti-inflammatory Secondary Prevention

News Conference News AHA 2019

COLCOT Renews Hope for Anti-inflammatory in Secondary Prevention: Colchicine

Caitlin E. Cox

November 16, 2019

News Daily News

Most Supplements and Diets Don’t Lower CVD or Mortality Risks

Michael O'Riordan

July 09, 2019

News Daily News

FDA Provides Update on Tainted ARB Investigation, With New Impurity Found

Todd Neale

March 04, 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for January 2019

Caitlin E. Cox

January 31, 2019

News Features

The Price of Knowledge: Industry-Sponsored Studies in the Era of Evidence-Based Medicine

Shelley Wood

October 22, 2018

News Daily News

Long-term Ticagrelor Post-MI of ‘Intermediate Value’: Cost-Effectiveness Study

Leah Lawrence

July 24, 2017

News Daily News

Drugs Most Heavily Promoted by Pharma Don’t Necessarily Offer the Best Health Value

Todd Neale

May 04, 2017

News Daily News

Semaglutide Cuts Risk of Major Cardiovascular Events in Type 2 Diabetes: SUSTAIN-6

Michael O'Riordan

September 16, 2016

Advertisement

Top Endovascular News of 2023

Inflammation More Powerful Than LDL as CV Risk Predictor in Statin-Free Patients

Two New Studies Highlight Lack of Diversity in Cardiovascular RCTs

Common ‘Heart’ Supplements Can’t Beat Statins: SPORT

USPSTF: Most Vitamin, Supplement Data Still ‘Inconclusive’ on CVD Benefits

Skipping Low-Value Cardiovascular Care Could Save Billions: AHA

Homozygous FH Diagnosis Often Comes Late, With Lackluster Care

FDA Issues New Guidance on Sodium Targets for Food Industry

Could an App Replace Statin Prescribing by Doctors?

New VARC-3 Definitions Provide a Road Map for Future Aortic Valve Research

Funding the Future: How Industry Support for CV Trials Could Evolve

COLCOT Renews Hope for Anti-inflammatory in Secondary Prevention: Colchicine

Most Supplements and Diets Don’t Lower CVD or Mortality Risks

FDA Provides Update on Tainted ARB Investigation, With New Impurity Found

TCTMD’s Top 10 Most Popular Stories for January 2019

The Price of Knowledge: Industry-Sponsored Studies in the Era of Evidence-Based Medicine

Long-term Ticagrelor Post-MI of ‘Intermediate Value’: Cost-Effectiveness Study

Drugs Most Heavily Promoted by Pharma Don’t Necessarily Offer the Best Health Value

Semaglutide Cuts Risk of Major Cardiovascular Events in Type 2 Diabetes: SUSTAIN-6

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content